Baxter International | BAX - Le Bénéfice D'Exploitation





Le Bénéfice D'Exploitation Changement Date
Abbott USD 2.13B 281M 2026-06
AngioDynamics USD -2.51M 5.41M 2025-09
Artivion USD 4.79M 6.85M 2025-12
AtriCure USD 9.66M 9.14M 2026-06
Baxter International USD 276M 210M 2026-06
Becton, Dickinson and Co. USD 752M 125M 2026-06
Boston Scientific USD 1.24B 190M 2026-06
Cooper Companies USD -31M 243.8M 2026-03
Dexcom USD 318.3M 63M 2026-06
Edwards Lifesciences USD 519.5M 4.8M 2026-06
Fresenius EUR 719M 118M 2026-06
Globus Medical USD -45.97M 209.97M 2026-06
Halozyme Therapeutics USD -63.72M 1.95M 2026-06
ICU Medical USD 60.43M 30.05M 2026-06
Inogen USD -7.79M 728K 2024-09
Insulet USD 129.7M 7.7M 2026-06
Integra LifeSciences USD 41.29M 29.82M 2026-06
Intuitive Surgical USD 977.6M 117.9M 2026-06
J&J USD 7.48B 860M 2026-06
Laboratory Of America USD 456.7M 46.6M 2026-06
Medtronic USD 2.09B 354M 2026-03
Merit Medical Systems USD 60.4M 16.25M 2026-06
Quest Diagnostics USD 459M 60M 2026-06
Smith & Nephew USD 505M 65M 2026-06
Stryker USD 1.79B 687M 2026-06
Tandem Diabetes Care USD -13.79M 3.64M 2026-06
Teleflex USD 73.07M 36.04M 2026-06
Terumo JPY 89.48B 58.03B 2026-06
Zimmer Biomet Holdings USD 344.7M 50.4M 2026-06